Proluciferin acetals as bioluminogenic substrates for cytochrome P450 activity and probes for CYP3A inhibition

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2403-2410

  Meisenheimer, Poncho L ^a   Uyeda, H Tetsuo ^a   Ma, Dongping ^b   Sobol, Mary ^b   McDougall, Mark G ^a   Corona, Cesear ^a   Simpson, Dan ^b   Klaubert, Dieter H ^a   Cali, James J ^b  

^a Promega Biosciences   (United States)

^b PROMEGA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CLOTRIMAZOLE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DISOPYRAMIDE; ERYTHROMYCIN; FLUORESCENT DYE; FLUVOXAMINE; KETOCONAZOLE; LUCIFERASE; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PROLUCIFERIN ACETAL; RECOMBINANT ENZYME; TESTOSTERONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BIOLUMINESCENCE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; MALE; OXIDATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYNTHESIS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; FIREFLY LUCIFERIN; HUMANS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MOLECULAR PROBES; SUBSTRATE SPECIFICITY;

EID: 81855183870     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041541     Document Type: Article

References (31)

1. Bell L, Bickford S, Nguyen PH, Wang J, He T, Zhang B, Friche Y, Zimmerlin A, Urban L, and Bojanic D (2008) Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery. J Biomol Screen 13:343-353. (Pubitemid 351793985)
2. Blanksby SJ and Ellison GB (2003) Bond dissociation energies of organic molecules. Acc Chem Res 36:255-263.
3. Branchini BR, Hayward MM, Bamford S, Brennan PM, and Lajiness EJ (1989) Naphthyl- and quinolylluciferin: green and red light emitting firefly luciferin analogues. Photochem Photobiol 49:689-695.
4. Cali JJ, Ma D, Sobol M, Simpson DJ, Frackman S, Good TD, Daily WJ, and Liu D (2006) Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2:629-645. (Pubitemid 46118331)
5. Cali JJ, Niles A, Valley MP, O'Brien MA, Riss TL, and Shultz J (2008) Bioluminescent assays for ADMET. Expert Opin Drug Metab Toxicol 4:103-120. (Pubitemid 351234104)
6. Doshi U and Li AP (2011) Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction. J Biomol Screen 16:903-909.
7. Fan F and Wood KV (2007) Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 5:127-136. (Pubitemid 46581246)
8. Friden M, Vanaja K, and Nandi VN (2006) Drug-drug interactions of anti-infective drugs: utility of fluorescence CYP inhibition assays in drug discovery. Drug Metabol Drug Interact 21:163-185. (Pubitemid 43971437)
9. Grime KH, Bird J, Ferguson D, and Riley RJ (2009) Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36:175-191.
10. Guengerich FP (2007) Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol 21:163-168.
11. Jones JP, Mysinger M, and Korzekwa KR (2002) Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metab Dispos 30:7-12. (Pubitemid 34016934)
12. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727. (Pubitemid 29520596)
13. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, and Böger RH (2000) Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504-513.
14. Larson B, Moeller T, Banks P, and Cali JJ (2011) Automated triplexed hepatocyte-based viability and CYP1A and -3A induction assays. J Biomol Screen 16:895-902.
15. Lazarou J, Pomeranz BH, and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205. (Pubitemid 28193431)
16. Li AP (2009) Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers. Drug Metab Dispos 37:1598-1603.
17. MacArthur R, Leister W, Veith H, Shinn P, Southall N, Austin CP, Inglese J, and Auld DS (2009) Monitoring compound integrity with cytochrome P450 assays and qHTS. J Biomol Screen 14:538-546.
18. Moody GC, Griffin SJ, Mather AN, McGinnity DF, and Riley RJ (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29:53-75. (Pubitemid 29050391)
19. Nomeir AA, Ruegg C, Shoemaker M, Favreau LV, Palamanda JR, Silber P, and Lin CC (2001) Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 29:748-753. (Pubitemid 32374578)
20. O'Brien MA, Daily WJ, Hesselberth PE, Moravec RA, Scurria MA, Klaubert DH, Bulleit RF, and Wood KV (2005) Homogeneous, bioluminescent protease assays: caspase-3 as a model. J Biomol Screen 10:137-148.
21. Stresser DM, Dehal SS, and Kupfer D (1996) Ring hydroxylation of [o-3H]methoxychlor as a probe for liver microsomal CYP2B activity: potential for in vivo CYP2B assay. Anal Biochem 233:100-107.
22. Veith H, Southall N, Huang R, James T, Fayne D, Artemenko N, Shen M, Inglese J, Austin CP, Lloyd DG, et al. (2009) Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 27:1050-1055.
23. Wang RW, Newton DJ, Liu N, Atkins WM, and Lu AY (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28:360-366. (Pubitemid 30137063)
24. White EH and Wörther H (1966) Analogs of firefly luciferin. 3. J Org Chem 31:1484-1488.
25. White EH, Worther H, Field GF, and McElroy WD (1965) Analogs of firefly luciferin. J Org Chem 30:2344-2348.
26. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833. (Pubitemid 41553963)
27. Woodroofe CC, Shultz JW, Wood MG, Osterman J, Cali JJ, Daily WJ, Meisenheimer PL, and Klaubert DH (2008) N-alkylated 6′-aminoluciferins are bioluminescent substrates for Ultra- Glo and QuantiLum luciferase: new potential scaffolds for bioluminescent assays. Biochemistry 47:10383-10393.
28. Zhou W, Andrews C, Liu J, Shultz JW, Valley MP, Cali JJ, Hawkins EM, Klaubert DH, Bulleit RF, and Wood KV (2008) Self-cleavable bioluminogenic luciferin phosphates as alkaline phosphatase reporters. Chembiochem 9:714-718.
29. Zhou W, Shultz JW, Murphy N, Hawkins EM, Bernad L, Good T, Moothart L, Frackman S, Klaubert DH, Bulleit RF, et al. (2006a) Electrophilic aromatic substituted luciferins as bioluminescent probes for glutathione S-transferase assays. Chem Commun (Camb) 4620-4622. (Pubitemid 44684559)
30. Zhou W, Valley MP, Shultz J, Hawkins EM, Bernad L, Good T, Good D, Riss TL, Klaubert DH, and Wood KV (2006b) New bioluminogenic substrates for monoamine oxidase assays. J Am Chem Soc 128:3122-3123.
31. Zientek M, Miller H, Smith D, Dunklee MB, Heinle L, Thurston A, Lee C, Hyland R, Fahmi O, and Burdette D (2008) Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 58:206-214.